Name of this trial: LIVIGNO-4
What type of cancer is this for? Non-Small Cell Lung Cancer, Non-Squamous Cell Cytology
Who is this trial for? Patients with Lung Cancer that has metastasized to other areas of body who have never received treatment for their disease.
What biomarkers are involved? NO EGFR, or NO ALK mutations allowed.
What is the National Clinical Trial #? NCT06236438
Brief summary of this trial: Randomized study looking at Livmoniplimab plus Budigalimab in combination with standard of care chemotherapy vs. Pembrolizumab plus standard of care chemotherapy.
Need to know: Patients must not have had any treatment for their metastatic lung cancer to be eligible for this trial. Patients may have received treatment for earlier stage of lung cancer as long as it was 6 months or greater from the time of progression of disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name: GENMAB
What type of cancer is this for? Non-small-cell lung cancer
Phase: II
Who is this trial for? Men and women who have non-small-cell lung cancer that has spread to other parts of their body.
What biomarkers are involved? Your tumor must have PD-L1 expression in greater than 1% of your tumor cells.
What is National Clinical Trial #? NCT05117242
Brief summary of trial: This study compares how well their new drug works (shrinks the tumors) by itself vs. giving it with “pembrolizumab”.
Need to know: You need to have had the standard treatment (chemo) and an “immune checkpoint inhibitor” as prior treatment.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]
Name of Trial: JUSTAR-001
What type of cancer is this trial for? Limited Stage, Small-cell Lung cancer
Who is this trial for? Patients with limited stage small cell lung cancer who have not progressed after initial chemotherapy/radiation.
What biomarkers are involved? None
National Clinical Trial # NCT06095583
Brief Summary of trial: Study is looking to compare and evaluate efficacy of new drug Tifcemalimab combined with Toripalimab vs. PLACEBO after consolidation chemotherapy for small cell lung cancer. This is a blinded study, so patients will not know whether they are receiving investigational drug or not.
Need to know information: Must not have received prior immunotherapy for small-cell lung cancer, and cannot have extensive stage/metastatic small cell lung cancer.
Where is this trial available? The Cancer and Hematology Centers and other sites nationwide, please click on link above for other potential sites.
For more information, please call 616-975-3065 or email [email protected]
Name: Pacific-9
What kind of cancer is this for? Non-small cell lung cancer
Phase: III
Who is this trial for? Men and women with locally advanced (Stage III) non-small cell lung cancer that cannot be removed by a doctor.
What biomarkers are involved? PD-L1, EGFR and ALK
What is National Clinical Trial #? NCT05221840
Brief summary of trial: This study is looking to prove that durvalumab and oleclumab work better than durvalumab and a placebo (harmless medication) do.
Need to know: You must have had a chemo plan that included either Cisplatin or Carboplatin, along with radiation at the same time you were getting chemotherapy. Your disease cannot have grown any bigger since chemo and radiation finished.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]
Name of Trial? Sunray-01
What type of Cancer is this for? Non-small cell Lung cancer
What biomarkers are involved? KRAS G12C-mutation, PD-L1 expression
National Clinical Trials # NCT06119581
Brief Summary of trial: Locally advanced, or metastatic non-small cell lung cancer, never treated. This is first line treatment with study drug LY3537982 (pill) or placebo, in combination with immunotherapy and chemotherapy.
Need to know information: No prior treatment for lung cancer. We will do mutation testing to determine eligibility from prior biopsy/blood sample. This is a blinded trial with study drug LY3537982/placebo. All patients will receive the oral drug but the provider nor research team will know whether you are getting drug/placebo.
Where is this trial available? The Cancer and Hematology Centers and other sites nationwide, please click on link above for other potential sites.
For more information, please call 616-975-3065 or email [email protected]